The following transcript has been edited for clarity.

Hi, my name is Margaret A. Chang, MD, MS, and I am a senior partner at Retinal Consultants Medical Group in Sacramento, California. I’m here at ASRS 2026, and I am presenting on the baseline risk factors for 15-letter vision loss in the ARCHER trial of vonaprument (formerly ANX007; Annexon Biosciences). Vonaprument is a nonpegylated Fab that targets C1q.

C1q is the main trigger for the classical complement cascade pathway and C1q tends to target intact synapses and get them to be removed by the immune system. It also does trigger C3 and C5 through the alternative complement cascade, and as we all know, that is a major trigger for geographic atrophy (GA) and cell loss. So what we’re thinking is that GA is a neurodegenerative disease. And so by targeting C1q and trying to get to this process a little bit sooner, that patients with GA may do better in the long term.

ARCHER was a phase 2 trial looking at vonaprument monthly or every other month vs sham. And basically the risk factors for 15-letter loss over time were patients who had slightly compromised vision but still had vision to lose. Patients between the vision of 20/40 and 20/100 were at highest risk of 15-letter loss. And also [patients with] subfoveal lesions were more at risk of 15-letter loss than nonsubfoveal lesions.

Those were the main findings of the study. This helped the study designers design the phase 3 ARCHER II study, which is going to read out later this year. RP